tients on NRTs, we would have incorrectly classified approximately 60% of our active smoking patients as abstainers or patients on NRTs (assuming no self-reporting status). This could potentially have dramatic results on the allocation of organs and markedly increase adverse outcomes in a transplantation setting.
Anabasine as a marker of active smoking in this ( Fig. 1) and a previous study (3 ) has been shown to have a very high clinical specificity. Virtually all nonsmokers will test negative for anabasine. However, our study and the larger Associated Regional and University Pathologists (ARUP) study demonstrated clinical sensitivities of only 41% and 20%, respectively. Therefore, in active smokers, there will be no detectable anabasine present the majority of the time. The possibilities of potential false negatives mostly with respect to the use of anabasine in monitoring NRT adherence have been documented (5 ) . Therefore, laboratories must be aware of the potential pitfalls when using this marker in the context of screening for transplantation eligibility. Based on our results and the larger ARUP study, patients who were active smokers could simply claim to be abstaining. It is reasonable to presume that many smokers already do so and in most cases would test negative for anabasine, giving no clarification about the actual status of the patient regarding tobacco use. A point of note, however, is that our study looked at patients' self-reported smoking status whereas the ARUP study used nicotine values as a means of categorizing patients.
Based on our finding of the low clinical sensitivity of the tobacco plant alkaloid anabasine in a transplant setting when used to determine eligibility for UNOS listing we argue that this marker should not be used alone to distinguish patients who are actively smoking from those who are on NRTs. We would advocate for also testing another tobacco alkaloid anatabine. Anatabine is not present in NRTs and is detectable at higher concentrations than anabasine in tobacco products, which could help improve the clinical sensitivity. The utility of anabasine therefore lies in the very high clinical specificity and would lend itself to use in smoke-stopping clinics where the marker could be trended over time and a disappearance would confirm cessation of smoking. However, in a transplant setting where organ allocation is contingent upon strict adherence to abstinence policies, anabasine only serves to further muddy the already murky waters. 
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To the Editor:
The discovery of circulating cell-free fetal DNA in maternal plasma in 1997 (1 ) has transformed the practice of prenatal testing (2 ) . The biological properties of the fetal-derived DNA in the plasma of a pregnant woman have been demonstrated to exhibit a number of differences from the maternal-derived DNA. Of note is that cell-free fetal DNA molecules are shorter than the maternal DNA molecules (3 ) and their overall methylation levels are lower than their maternal counterparts (4 ). However, the understanding of how the methylation and size profiles would change across different gesta-tional ages remains incomplete. In this study, we investigated whether one could use the temporal changes in maternal plasma DNA to obtain information regarding the gestational age. We obtained peripheral blood samples with informed consent and institutional approval from 10 pregnant women from each of the first (12-14 weeks), second (20 -23 weeks), and third (38 -40 weeks) trimesters and harvested the plasma and maternal buffy coat from each case. Fetal samples were also obtained by chorionic villus sampling, amniocentesis, or sampling of the placenta, depending on whether a case was from the first, second, or third trimester, respectively.
The maternal buffy coat and fetal samples were genotyped using a microarray platform (HumanOmni2.5, Illumina). There was a median of 195331 informative single nucleotide polymorphism loci (range: 146428 -202800) for which the mother was homozygous and the fetus was heterozygous. Plasma DNA molecules that carried the fetalspecific alleles were identified as derived from the fetus. The median fetal DNA fraction among those samples was 17.1% (range: 7.0%-46.8%). Genome-wide paired-end bisulfite sequencing was applied to plasma DNA samples (4, 5 ) . A median of 103 million (range: 52-186 million) mapped and nonduplicated pairedend reads was obtained for each case, which was equivalent to a median sequencing depth of 5-fold haploid genome coverage with 92% of genome-wide CpGs sequenced. The fetal-specific reads covered 36115 (range: 17252-57980), 35914 (range:
22815-68624), and 134671 (range: 92580 -176996) CpG sites for the first-, second-, and third-trimester maternal plasma samples, respectively. The methylation level of the fetal DNA was expressed as the proportion of CpGs that were methylated among the sequenced fetal-specific DNA molecules of each sample. The median methylation levels were found to be 42.2% (range: 37.0%-45.7%), 46.8% (range: 43.6%-51.0%), and 52.9% (range: 51.1%-55.6%) for the first-, second-, and thirdtrimester plasma samples, respectively. The methylation level of fetal DNA was found to increase as the gestational age progressed (Fig. 1) , rising up by 25% (P value Ͻ0.0001, Mann-Whitney test) in the third trimester when compared with the first trimester. The methylation levels in the second-trimester group were between the values for the firstand third-trimester groups. However, there was no statistically significant change (P value ϭ 0.2) for the methylation levels of maternalderived DNA between the first (median: 68.9%, range: 65.7%-71.4%) and third trimesters (median: 70.0%, range: 69.4%-71.3%).
The size profile of maternal plasma DNA was determined via the coordinates of the outermost nucleotide at each end of the aligned paired-end reads. In a previous study, the sizes of cell-free DNA in maternal plasma were reported to be positively correlated with the DNA methylation level (4 ). Thus, we quantified the proportion of long DNA fragments (Ն150 bp) for each plasma sample. Interestingly, the proportion of fetal-derived long DNA fragments also increased as the gestational age progressed (Fig. 1) . The median proportions of fetalderived long DNA fragments were 45.6% (range: 38.3%-49.9%), 48.6% (range: 42.6%-57.7%) and 54.0% (range: 49.2%-59.7%) for the first-, second-, and thirdtrimester plasma samples, respectively. A median of the proportion of fetal-derived long DNA increased by 18% (P value Ͻ0.0001) in the third trimester when compared with the first trimester. Such long fetal DNA in the third trimester was concentrated in a range of 150 -200 bp. On the other hand, the median size of maternal-derived DNA increased only by 7% (P value ϭ 0.001) as shown by a comparison between the first (median: 73.8%, range: 69.6%-75.7%) and third (median: 78%, range 73.5%-79%) trimesters. The proportion of fetal-derived The first-, second-and third-trimester samples are represented in red, green, and blue dots, respectively. The x axis represents the methylation level and the y axis represents the proportion of long fragment (≥150 bp).
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Clinical Chemistry 63:2 (2017) 607 long DNA in the second-trimester group was shown to be between the values of the first-and third-trimester groups. As shown in Fig. 1 , by combining these 2 parameters, one could obtain a reasonable separation of samples from the 3 gestational age groups, indicating the feasibility of molecular gestational dating using maternal plasma DNA characteristics. Future work could involve the validation of the present data using an expanded sample size, as well as the identification of methylation markers whose methylation levels would be more strongly correlated with the gestational age. 
